TY  - JOUR
AU  - Schettini, Francesco
AU  - Giuliano, Mario
AU  - Lambertini, Matteo
AU  - Bartsch, Rupert
AU  - Pinato, David James
AU  - Onesti, Concetta Elisa
AU  - Harbeck, Nadia
AU  - Lüftner, Diana
AU  - Rottey, Sylvie
AU  - van Dam, Peter A.
AU  - Zaman, Khalil
AU  - Mustacchi, Giorgio
AU  - Gligorov, Joseph
AU  - Awada, Ahmad
AU  - Campone, Mario
AU  - Wildiers, Hans
AU  - Gennari, Alessandra
AU  - Tjan-Heijnen, Vivianne C. G.
AU  - Cortes, Javier
AU  - Locci, Mariavittoria
AU  - Paris, Ida
AU  - Del Mastro, Lucia
AU  - De Placido, Sabino
AU  - Martín Jiménez, Miguel José
AU  - Jerusalem, Guy
AU  - Venturini, Sergio
AU  - Curigliano, Giuseppe
AU  - Generali, Daniele
PY  - 2021
DO  - 10.3390/cancers13174421
SN  - 2072-6694
UR  - https://hdl.handle.net/20.500.14352/4754
T2  - Cancers
AB  - Anthracyclines are among the most active chemotherapies (CT) in breast cancer (BC). However, cardiotoxicity is a risk and peculiar side effect that has been limiting their use in clinical practice, especially after the introduction of taxanes....
LA  - eng
M2  - 4421
PB  - MPDI
KW  - anthracyclines
KW  - breast cancer
KW  - triple negative
KW  - hormone receptor
KW  - metastatic
KW  - non-pegylated liposomal doxorubicin
TI  - Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer
TY  - journal article
VL  - 13
ER  -